Related Experiment Videos
Enhancing antiepileptic drug adherence: a randomized controlled trial
Ian Brown1, Paschal Sheeran, Markus Reuber
1Department of Psychology, University of Sheffield, Western Bank, Sheffield S10 2JF, UK.
Epilepsy & Behavior : E&B
|October 30, 2009
Summary
Improving antiepileptic drug (AED) adherence is crucial for epilepsy management. A simple implementation intention intervention significantly boosted medication adherence in patients with epilepsy, reducing risks associated with suboptimal treatment.
Area of Science:
- Neurology
- Behavioral Science
- Clinical Pharmacy
Background:
- Suboptimal adherence to antiepileptic drugs (AEDs) is common in epilepsy management.
- Poor adherence increases risks of seizures, status epilepticus, and sudden unexplained death in epilepsy (SUDEP).
Purpose of the Study:
- To evaluate the effectiveness of an implementation intention intervention in improving AED treatment adherence.
- To assess if a simple self-administered questionnaire can enhance medication adherence in epilepsy patients.
Main Methods:
- A randomized controlled trial involving 81 patients with epilepsy.
- A 1-month monitoring period using electronic pill bottle opening registration (Medication Event Monitoring System [MEMS]).
- Intervention group completed a questionnaire linking medication intake intention with time, place, and activity.
Main Results:
- Intervention participants demonstrated significantly improved adherence compared to controls (P<0.01).
- Higher total doses taken (93.4% vs. 79.1%), more days with correct dosage (88.7% vs. 65.3%), and better on-schedule dosing (78.8% vs. 55.3%).
Conclusions:
- Implementation intention interventions are effective and easy to administer for promoting AED adherence.
- This strategy offers a practical approach to enhance medication adherence in epilepsy patients.
Related Concept Videos
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...